BioAQ 2026 Event: Biopharmaceutical Quality, CMC, and Analytics

Foreword

From early R&D to commercialization, quality analysis is the lifeline of biopharmaceuticals.

The 4th BioAQ Biopharmaceutical Analysis & Quality Conference will be grandly held on April 2–3, 2026, in Shanghai.

As one of the organizers, Hzymes has long been dedicated to advancing quality control in the biopharmaceutical industry. To foster in-depth collaboration across the entire value chain, we are proud to host this high-level industry event and sincerely invite partners, clients, and professionals to join us for knowledge exchange and future collaboration.

Event Information

Date: April 2–3, 2026

Venue: Hilton Shanghai Fengxian (No. 818 Rongqin Road, Fengxian District, Shanghai)

Transportation: Complimentary shuttle service available

Scale: 500 attendees

Guiding Organizations:

Shanghai Biomedical Technology Industry Promotion Center
Shanghai Fengxian District Science and Technology Commission

Organizer:

China Association for Quality Promotion in Food & Pharmaceutical Enterprises

Co-organizers:

Hzymes Biotechnology Co., Ltd.
Shanghai Hanover Biotechnology Co., Ltd.
Best Media

Supporting Organizations:

School of Life Science and Technology, Shanghai Jiao Tong University
School of Biomedical Engineering, Shanghai Jiao Tong University
School of Pharmacy, Shanghai Jiao Tong University
Shanghai Industrial Comprehensive Development Zone
Shanghai Biomedical Association
Institute of Key Raw Materials, Shanghai Institute of Experimental Medicine

Advisory Committee:

Conference Overview

Led by distinguished academicians, 60+ expert speakers will explore the future of biopharmaceutical analysis and quality.

The conference features a main forum on “Quality Analysis & Regulatory Compliance”, alongside 3 parallel forums and 10 specialized sessions, covering:

Latest Chinese Pharmacopoeia updates and regulatory trends
Protein therapeutics, cell therapy, peptides, and XDC drugs
From regulatory interpretation to process development and commercialization

Key Highlights

1. Insights into Cutting-Edge Technologies

Focus on protein therapeutics (antibodies, fusion proteins, recombinant proteins, ADCs), peptide/XDC conjugates, and cell therapies (CAR-T, CAR-NK, CRISPR). Industry experts will share global innovation trends and future opportunities.

2. End-to-End QC & Analytical Technologies

From structural characterization and impurity profiling to CQA identification and digital QC, this session showcases advanced tools, automation platforms, and real-world case studies.

3. Process Innovation & Scale-Up Practices

Deep dives into ADC/XDC development, purification challenges, scale-up production, and cell therapy process optimization—featuring industrialization and regulatory submission strategies.